| Project/Area Number |
22591043
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Hematology
|
|---|
| Research Institution | Sapporo Medical University |
|---|
Principal Investigator |
SATO Tsutomu 札幌医科大学, 医学部, 講師 (40404602)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
KOBUNE Masayoshi 札幌医科大学, 医学部, 准教授 (90336389)
加藤 淳二 札幌医科大学, 医学部, 教授 (20244345)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
KATO Junji 札幌医科大学, 医学部, 教授 (20244345)
|
|---|
| Project Period (FY) |
2010 – 2012
|
| Project Status |
Completed (Fiscal Year 2012)
|
| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2012: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2011: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2010: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | リンパ腫 / オートファジー / mTOR / 治療 |
|---|
| Research Abstract |
Malignant lymphoma has been one of the hematological malignancies of which prognosis is still poor. The most possible reason of poor-prognosis is the resistance against conventional chemotherapeutic reagents, which are expected to induce apoptotic and/or necrotic death in lymphoma cells. Therefore, novel therapy with unique mechanism is required. Then, we have chosen the strategy inducing autolytic cell death, autophagy since the signaling of autophagic cell death does not depend on the apoptotic and necrotic signaling. For the induction of autophagy, we have used siRNA against mTOR. For the delivery of siRNA and the targeting of B-cell lymphoma, we have developed anti-CD19-targeted siRNA-PEG/KALA PECM system.
|
